Cited by 70Natural Products and Biological ResearchLipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: The available clinical data

Cicero, Arrigo F.G., Colletti, Alessandro·2016·Phytomedicine

Abstract

Background Cardiovascular diseases are the primary cause of death and the leading cause of disability in industrialized countries. Dyslipidemia is a major independent and reversible risk factor for these diseases: it is estimated that a reduction of 1 mmol/l (38 mg/dl) of LDL cholesterol is associated with a risk of developing a cardiovascular complication reduced by 25%, a reduction potentially achieved by life-style improvement associated to adequate dietary supplementation with bioactive substances.Aim The aim of this review is to focus on the major phytochemical nutraceuticals combinations supported by clinical trials that have demonstrated positive effects in the treatment of dyslipidemia.Main text There are many nutraceuticals with significant lipid-lowering properties: most of them are used in association with a low dosage, because that permits to reduce the risk of side effects and theoretically to improve efficacy. In fact, natural products with different synergetic lipid-lowering could be combined: they can reduce the absorption of lipids from the bowel and/or increase their excretion (soluble fibers, plant sterols, probiotics), enhance the hepatic uptake of cholesterol (berberine, soybean proteins), inhibit Hydroxy-Methil-Gglutaryl Coenzyme A reductase enzyme and consequently the hepatic synthesis of cholesterol (monacolins, policosanols, allicin, soybean proteins, bergamot); furthermore some products are able to reduce the oxidation of the LDL and increase the thermogenesis and lipid metabolism (chlorogenic acid).Conclusion Rational combinations of nutraceuticals with different lipid-lowering activities, whether associated with an appropriate lifestyle, should provide an alternative to drug treatment in patients in primary cardiovascular disease prevention with mildly added cardiovascular risk and in some statin-intolerant patients.

Integrity signals

Registry

Crossref · 10.1016/j.phymed.2015.10.011

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Rational combinations of nutraceuticals with different lipid-lowering activities, particularly when associated with an appropriate lifestyle, can provide an alternative to drug treatment in patients in primary CVD prevention with mildly elevated LDL-C and in some statin-intolerant patients.

    “Rational combinations of nutraceuticals with different lipid-lowering activities (Fig. 1), particularly when associated with an appropriate lifestyle, can provide an alternative to drug treatment in patients in primary CVD prevention with mildly elevated LDL-C (especially for those not being at their target LDL-C)) and in some statin-intolerant patients [90].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cicero, A. F. G., & Colletti, A.
Affiliations
University of Bologna (IT)
Corresponding author
Cicero, Arrigo F.G.
Venue
Phytomedicine
Publisher
Elsevier BV
Published
2016-10
Volume
23
Issue
11
Pages
1113-1118
ISSN
0944-7113 (ISSN-L)
OpenAlex
W2169299785
Cited by
70
References
69
Citations by year
2026: 4 · 2025: 4 · 2024: 6 · 2023: 5 · 2022: 2 · 2021: 6 · 2020: 11 · 2019: 6 · 2018: 5 · 2017: 11 · 2016: 10
FWCI
8.73
Type
journal article
Language
en
Open access
closed
Locations
  • Phytomedicine (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Natural Products and Biological Research
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
dyslipidemia, nutraceuticals, hypolipidemic activity, phytosterols, soluble dietary fiber, probiotics, berberine, soy protein, monacolins, policosanol, allicin, bergamot, chlorogenic acid, LDL oxidation, HMG-CoA reductase inhibition, cholesterol absorption, statin intolerance, cardiovascular disease prevention, dietary supplementation
MeSH terms
Berberine, Biological Products, Cholesterol, Clinical Trials as Topic, Drug Therapy, Combination, Fatty Alcohols, Humans, Lipids, Phytotherapy, Phytosterols, Plant Proteins, Silymarin, Dietary Supplements, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review